Worldwide Small Molecule API Industry to 2027 - Featuring Aurobindo Pharma, Cambrex and Catalent Among Others
14 mai 2021 05h18 HE | Research and Markets
Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Global Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application...
Global $250+ Billion Active Pharmaceutical Ingredient (API) Market to 2025
06 mai 2021 04h23 HE | Research and Markets
Dublin, May 06, 2021 (GLOBE NEWSWIRE) -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug...
Global Small Molecule Targeted Cancer Oncology Drug Therapeutics Market Size Sales To Reach US$ 130 Billion By 2026 Says Kuick Research
18 sept. 2020 14h12 HE | KuicK Research
DELHI, India, Sept. 18, 2020 (GLOBE NEWSWIRE) -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: Global Small Molecule Cancer...
7 Hills Logo.png
7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
04 juin 2020 12h58 HE | 7 Hills Pharma
Company is leveraging its integrin platform technology to improve effectiveness of immunotherapies, including Covid-19 vaccines HOUSTON, June 04, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a...
HitGen Announces Innovative Drug Discovery Research Collaboration with LG Chem by Applying DNA-Encoded Technology
16 août 2018 20h00 HE | HitGen Ltd.
CHENGDU, China, Aug. 17, 2018 (GLOBE NEWSWIRE) -- HitGen Ltd today announced a multi-year major drug discovery research collaboration with LG Chem to identify novel small molecule leads for targets...
HitGen Launching Initiative to Discover New Medicines to Combat Tuberculosis and Malaria
02 août 2018 20h00 HE | HitGen Ltd.
CHENGDU, China, Aug. 03, 2018 (GLOBE NEWSWIRE) -- HitGen Ltd., a privately held biotech company, announced today a three-year grant from the Bill & Melinda Gates Foundation. The grant will be...
Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.
12 déc. 2016 07h38 HE | Neuralstem, Inc.
GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
04 nov. 2008 09h00 HE | HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle...
HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders
17 janv. 2008 09h00 HE | HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - January 17, 2008) - HemaQuest Pharmaceuticals, which received its first round of venture financing three months ago, today announced that the U.S. Food and Drug...
HemaQuest Announces $20M Series A Financing for Anemia Drug Development
01 nov. 2007 10h30 HE | HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - November 1, 2007) - HemaQuest Pharmaceuticals, a new company developing proprietary small molecule therapeutics to treat serious blood disorders, today announced that it...